FIELD: pharmaceuticals.
SUBSTANCE: invention relates to recombinant human growth hormone (rhGH) prodrug conjugates, wherein the molecular weight of the prodrug without hGH-NH is at least 30 kDa and a maximum is 120 kDa. Also a method of treatment of diseases associated with growth hormone in humans using the above-described conjugates is described.
EFFECT: obtaining a pharmaceutical composition and a method of treatment of growth hormone-related diseases in humans.
9 cl, 11 dwg, 27 ex, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING GROWTH HORMONE-ASSOCIATED DISEASES IN HUMANS | 2014 |
|
RU2689336C2 |
PEGYLATED COMPOUNDS OF RECOMBINANT HUMAN GROWTH HORMONE | 2009 |
|
RU2530714C9 |
NOVEL POLYMER hGH PRODRUGS | 2015 |
|
RU2718664C2 |
METHOD OF CONJUGATING PEPTIDES, MEDIATED BY TRANSGLUTAMINASE | 2005 |
|
RU2385879C2 |
HYDROCARBON GEL-BASED PRODRUGS | 2013 |
|
RU2647729C2 |
VEGF NEUTRALISING PRODRUGS FOR THE TREATMENT OF OCULAR CONDITIONS | 2013 |
|
RU2673881C2 |
PHARMACEUTICAL COMPOSITION CONTAINING Fc-REGION OF IMMUNOGLOBULIN AS CARRIER | 2004 |
|
RU2352583C2 |
PRODRUGS CONTAINING INSULIN LINKER CONJUGATE | 2010 |
|
RU2574667C2 |
CONJUGATE OF POLYETHYLENE GLYCOL- G-CSF | 2006 |
|
RU2423133C2 |
PEG-CONTAINING CONJUGATES OF HGF-NK4 | 2002 |
|
RU2293574C2 |
Authors
Dates
2023-08-23—Published
2019-05-14—Filed